Baricitinib and İmuran 50 mg: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Potent immunosuppressants can add to baricitinib immunosuppression.
Clinical significance and safety
For chronic rheumatoid arthritis or alopecia treatment, the baricitinib label does not recommend combination with potent immunosuppressants such as the ingredient in İmuran 50 mg. Infection and other immunosuppression risks require a specialist plan. This statement must not be used to alter a hospital COVID-19 regimen independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.